BELGRADE, Mont., April 6, 2015 (GLOBE NEWSWIRE) — Bacterin International Holdings, Inc. (NYSE MKT:BONE), a leader in the development of revolutionary bone grafts, is pleased to announce that the United States Patent and Trademark Office has issued US Patent No. 8,992,964 entitled “Process for Demineralization of Bone Matrix with Preservation of Natural Growth Factors.” The issued claims in the patent cover certain demineralized bone matrixes containing minimum levels of bone morphogenetic protein-2 (BMP-2), which include products in Bacterin’s OsteoSponge® product line. Bacterin has pending continuing applications in the United States to pursue protection on other aspects of its bone demineralization technology.
Bacterin’s Chief Scientific Officer, Gregory Juda, commented, “We are pleased to receive this patent that protects our proprietary demineralized bone products and recognizes the long term innovation of our company. This patent further substantiates our core competency in demineralized bone matrix technology and we are committed to maintaining our role as a leader in advancing orthobiologic technology.”
The OsteoSponge® technology is two-fold; it allows for the allograft comprised of human bone to become compressible, while maintaining the spectrum of native growth factors inherent to bone. These growth factors are essential for the tissue regeneration process in the patient’s body. Because of this unique combination of properties, clinical investigators have been able to show fusion rates greater than 97 percent in peer-reviewed, published studies. Bacterin was the first company to commercialize a compressible DBM sponge marketed specifically for its handling characteristics, osteoconductive architecture, and osteoinductive properties for orthopedic bone grafting applications.
